The Bill & Melinda Gates Foundation must have liked what it saw in an initial collaboration with Exscientia to find new antivirals for COVID-19 and related diseases.
Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part
Artificial intelligence-based drug discovery company Exscientia is stepping up its search for new COVID-19 medicines, thanks to an award by the Bill & Melinda Gates Foundation.
The UK's biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry
UK-based artificial intelligence pioneer Exscientia has made a play to stay at the forefront of the field, acquiring Austrian rival Allcyte with the help of its recent $525 million financin
Exscientia has signed up another big pharma partner for its artificial intelligence (AI) based drug discovery platform, this time attracting a $50 million upfront buy-in from Bristol-Myers